Stockpolly
Search
Delisting risk
PHIO · NASDAQ · Biotechnology

Phio Pharmaceuticals (PHIO)

Develops PH-762, a self-delivering RNAi therapy injected into skin tumors.

$1.05
Pre-market−0.08 (−7.08%)
At close$1.13(+2.73%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue201111011100
Gross profit−20−1−1−1−10−1−1−100
121111211144
Research & development211111111133
111111111111
General & administrative101111111111
Other expenses−20−1−1−1−10−1−1−100
Operating income−3−2−2−2−2−2−2−2−3−3−4−4
000000000000
Interest income000000000000
Other non-operating income000000000000
Income before tax−3−2−2−2−2−2−2−2−2−2−4−4
Net income from continuing operations−3−2−2−2−2−2−2−2−2−2−4−4
Net income−3−2−2−2−2−2−2−2−2−2−4−4
EPS, basic−$10.26−$4.56−$4.24−$3.62−$1.54−$0.37−$41,070.15−$0.45−$0.44−$0.20−$0.34−$0.36
EPS, diluted−$10.26−$4.56−$4.24−$3.62−$1.54−$0.37−$41,070.15−$0.45−$0.44−$0.20−$0.34−$0.36
Weighted average shares, basic001111455121212
Weighted average shares, diluted001111455121212
EBITDA−3−2−2−2−2−2−2−2−2−2−4−4
Depreciation & amortization000000000000
EBIT−3−2−2−2−2−2−2−2−2−2−4−4